Form 8-K · Current Report · Filed 2026-03-04

Moderna Settles Patent Infringement Litigation with Arbutus/Genevant

On March 3, 2026, Moderna, Inc. (Moderna) entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH (Arbutus/Genevant) to resolve all patent infringement litigation pending in the U.S. and internationally. Moderna will make a $950 million noncontingent lump sum payment to Arbutus/Genevant by July 8, 2026. An additional contingent payment of up to $1.3 billion may be due if Moderna does not prevail on its appeal to the Court of Appeals for the Federal Circuit regarding the applicability of 28 U.S.C. § 1498 to the litigation. The Settlement Agreement also includes a fully paid-up, royalty-free, worldwide license for Moderna to use certain Arbutus/Genevant patents related to its infectious disease vaccines and a covenant not to sue. This settlement provides certainty for Moderna's full infectious disease portfolio, including future vaccine pipeline.